Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
For tailored, clinician-led support, Mayfair Weight Loss Clinic can help you assess your options and continue your weight loss journey with clarity and confidence
Your PlexusDx provider reviews your progress at regular check-ins and adjusts your approach to keep results on track
Druzhyna, N., Szczesny, B., Olah, G., Modis, K., Asimakopoulou, A., Pavlidou, A
Semaglutide & Tirzepatide Weight Loss Programs in 2025: How Sprout Health is Redefining Telehealth Care UPDATE - Contact information has been updated on this release as of September 9, 2025 A remote-first, doctor-reviewed telehealth program offering access to personalized care plans and GLP-1 evaluations using semaglutide or tirzepatide
GLP-1 receptor agonists (semaglutide, liraglutide) are broken down by enzymes throughout the body rather than through liver metabolism Clinical evidence shows these medications may reduce liver fat content and improve liver enzyme levels through weight loss and improved insulin sensitivity Gallbladder disorders including gallstones and cholecystitis occur more frequently during treatment, particularly with rapid weight loss Patients with severe hepatic impairment (Child-Pugh class C) require specialist hepatology input before initiating treatment Baseline liver function tests should be considered before starting treatment, particularly in patients with risk factors for liver disease Immediate medical attention is required for jaundice, severe abdominal pain, fever with abdominal pain, or unexplained bruising during treatment Table of Contents Understanding Weight Loss Injections and Liver Health How GLP-1 Receptor Agonists Affect the Liver Potential Liver-Related Side Effects and Risks Who Should Avoid Weight Loss Injections Due to Liver Concerns Monitoring Liver Function During Treatment When to Seek Medical Advice About Liver Health Frequently Asked Questions Understanding Weight Loss Injections and Liver Health Weight loss injections, particularly GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda), have become increasingly popular for managing obesity and type 2 diabetes in the UK
